SynthesisStem cell research & therapy2025
Platelet-rich plasma (PRP) and the future of male fertility: a path forward for personalized and regenerative therapies.
Synthesis in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Platelet-released growth factors promote pro-angiogenic effects in endothelial cells: a translational perspective on wound healing and regenerative medicine.Stem cell research & therapy · 2026Article
- Platelet-rich plasma hydrogel supports long-term germ cell maintenance in rat testicular organotypic culture.Journal of assisted reproduction and genetics · 2026Article
- The effect of intratesticular autologous platelet-rich plasma injection on sperm DNA fragmentation in men with oligoasthenoteratozoospermia: An RCT.International journal of reproductive biomedicine · 2026Article
- Effects of Platelet-Rich Plasma Dose and Application Strategy on Post-Thaw Spermatological Parameters in Goat Semen.Veterinary sciences · 2026Article
- Platelet-Rich Plasma in Sperm Processing for Assisted Reproductive Technology: Molecular Mechanisms, Clinical Applications, and Future Directions.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet-rich plasma (PRP) and its subtype, plasma rich in growth factors (PRGF), are autologous blood-derived products that have garnered increasing attention as personalized therapeutic tools in the field of male fertility. This systematic review aims to evaluate the current in vitro and in vivo evidence regarding the potential applications of platelet-derived products in various domains of male reproductive health, including in vitro spermatogenesis, sperm preservation, treatment of male infertility, mitigation of testicular toxicity, and management of testicular torsion/detorsion (T/D) injury. STRATEGY: This review was conducted in accordance with PRISMA guidelines and was prospectively registered in PROSPERO. A comprehensive and language-unrestricted search was performed across major databases, including the Cochrane Library, MEDLINE/PubMed, Scopus, ScienceDirect, and Web of Science. Studies published up to October 2024 were included, with an update in January 2025. Three reviewers independently screened and selected studies, with discrepancies resolved through discussion or consultation with a fourth reviewer.
resultsA total of 43 studies met the inclusion criteria. Available evidence suggests that PRP and PRGF supplementation in culture media may enhance in vitro sperm generation by improving cell viability and proliferation. Their incorporation into sperm incubation and cryopreservation protocols has also been associated with improved motility, viability, and structural integrity. In vivo studies indicate that intratesticular PRP injections may offer therapeutic benefits for male infertility, potentially supporting improvements in sperm parameters, hormonal balance, and testicular tissue restoration. Additionally, PRP has been reported to reduce testicular toxicity and ischemia-reperfusion injury, possibly through antioxidative and tissue-reparative mechanisms.
conclusionWhile preliminary findings highlight the promise of PRP and PRGF as emerging, plasma-based approaches in male reproductive medicine, further research is essential to standardize protocols, evaluate long-term efficacy and safety, and elucidate underlying molecular mechanisms before these therapies can be safely and effectively translated into routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.